Post by miamianne67 on Jan 2, 2017 14:43:54 GMT
3 Biotech Stocks That Turned $10,000 Into Over $100,000
How Opko Health, Incyte, and China Biologic Products made fortunes for shareholders who bought and held on to the biotech stocks.
Keith Speights (TMFFishBiz) Dec 31, 2016 at 12:04PM
Some biotech stocks have made shareholders a lot of money over the last decade. Few, though, have performed as well as Opko Health (NASDAQ:OPK), Incyte (NASDAQ:INCY), and China Biologic Products (NASDAQ:CBPO). These three biotech stocks turned an initial investment of $10,000 into more than $100,000 in just 10 years. Here's how they did it.
Opko Health: Acquiring growth
Opko's share price is up around 1,250% in the last 10 years, enough to turn $10,000 into over $110,000. The biotech's name hints at its early roots in developing ophthalmic pharmaceuticals and ophthalmic diagnostic and imaging systems. Through the years, though, Opko acquired other businesses that expanded its focus -- and drove its stock up tremendously.
2013 was a pivotal year for Opko. The company more than doubled its revenue thanks primarily to its purchases in the previous year of laboratory service provider Prost-Data and European pharmaceutical and veterinary products company Farmadiet.
Today, Opko claims a large diagnostics business, with the nation's third-largest clinical laboratory with a core genetic testing focus and products including prostate cancer screening test 4Kscore and the Claros 1 in-office immunoassay platform. Opko's pharmaceutical business unit features secondary hyperparathyroidism drug Rayaldee and chemotherapy-induced nausea and vomiting drug Varubi.
Opko continues to grow through acquisitions, most recently with its purchase of Canadian biotech Transition Therapeutics. The company recently announced disappointing results from a late-stage study of a long-acting human growth hormone in development with Pfizer, but still hopes to be able to move forward with the product.
How Opko Health, Incyte, and China Biologic Products made fortunes for shareholders who bought and held on to the biotech stocks.
Keith Speights (TMFFishBiz) Dec 31, 2016 at 12:04PM
Some biotech stocks have made shareholders a lot of money over the last decade. Few, though, have performed as well as Opko Health (NASDAQ:OPK), Incyte (NASDAQ:INCY), and China Biologic Products (NASDAQ:CBPO). These three biotech stocks turned an initial investment of $10,000 into more than $100,000 in just 10 years. Here's how they did it.
Opko Health: Acquiring growth
Opko's share price is up around 1,250% in the last 10 years, enough to turn $10,000 into over $110,000. The biotech's name hints at its early roots in developing ophthalmic pharmaceuticals and ophthalmic diagnostic and imaging systems. Through the years, though, Opko acquired other businesses that expanded its focus -- and drove its stock up tremendously.
2013 was a pivotal year for Opko. The company more than doubled its revenue thanks primarily to its purchases in the previous year of laboratory service provider Prost-Data and European pharmaceutical and veterinary products company Farmadiet.
Today, Opko claims a large diagnostics business, with the nation's third-largest clinical laboratory with a core genetic testing focus and products including prostate cancer screening test 4Kscore and the Claros 1 in-office immunoassay platform. Opko's pharmaceutical business unit features secondary hyperparathyroidism drug Rayaldee and chemotherapy-induced nausea and vomiting drug Varubi.
Opko continues to grow through acquisitions, most recently with its purchase of Canadian biotech Transition Therapeutics. The company recently announced disappointing results from a late-stage study of a long-acting human growth hormone in development with Pfizer, but still hopes to be able to move forward with the product.